Loading...
Market
What will be J&J's operational sales growth for 2024?
2
Resolution / Starting Odds
5.7% to 6.2% • 25%
Less than 5.7% • 25%
More than 6.2% • 25%
Other • 25%
Johnson & Johnson's official financial report for the fiscal year 2024
Story
Johnson & Johnson Q3 EPS $2.42 Beats Estimates, Raises Revenue Forecast
Oct 15, 2024, 10:24 AM
Johnson & Johnson reported stronger-than-expected financial results for the third quarter of 2024, with adjusted earnings per share of $2.42 surpassing analysts' estimates of $2.19, although down 9% year-over-year. The company's revenue increased by 5.2% year-over-year to $22.47 billion, exceeding expectations of $22.16 billion. Net income stood at $2.69 billion, a decrease of 37.5% from the previous year. Pharmaceutical sales were a significant contributor, with medicine revenue totaling $14.58 billion, above the projected $14.12 billion, driven by strong sales of oncology drugs. Despite lower MedTech sales of $7.89 billion compared to the estimated $8.03 billion, the overall performance led Johnson & Johnson to adjust its full-year 2024 guidance. The company raised its revenue forecast to a range of $88.4 billion to $88.8 billion from the previous $88 billion to $88.4 billion and increased its operational sales growth outlook to 5.7–6.2% year-over-year. However, it slightly lowered its adjusted earnings per share guidance to $9.88 to $9.98 from the earlier $9.97 to $10.07.
View original story
Similar markets
Below $21 billion • 25%
$21 billion to $22 billion • 25%
$22 billion to $23 billion • 25%
Above $23 billion • 25%
10% - 12% • 25%
13% - 15% • 25%
16% - 18% • 25%
Above 18% • 25%
Above $175 • 25%
Between $150 and $175 • 25%
Between $125 and $150 • 25%
Below $125 • 25%
Below $2.50 • 25%
$2.50 to $2.70 • 25%
$2.71 to $2.90 • 25%
Above $2.90 • 25%
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly underperform • 25%
Below 9.5% • 25%
9.5% - 9.6% • 25%
9.7% - 9.8% • 25%
9.9% - 10.0% • 25%
Less than $10 billion • 25%
$10 billion to $15 billion • 25%
$15 billion to $20 billion • 25%
More than $20 billion • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
< 0% • 25%
0% to 0.5% • 25%
0.6% to 1% • 25%
> 1% • 25%